Skip To Main Content
Barbara Burtness on Muck Rack

Barbara Burtness

As seen in: Nature, Wiley Online Library, MDPI, JAMA Oncology, The Lancet, Healio, HemOnc Today, Newswise, NewsBreak, Journal of Clinical Oncology and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbara

Contact Barbara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Safusidenib Earns FDA Fast Track Designation for IDH1-Mutant Glioma

|
By Tim Cortese, Russ Conroy, Barbara Burtness
| ONCOLOGY journal Verified
The FDA has granted fast track designation to safusidenib, an investigational, oral, brain-penetrant selective inhibitor of mutant IDH1, for the treatment of patients with IDH1-mutant glioma, according to a news release from the company.1 The designation is supported by favorable data from safusidenib in this patient population.
Open in Who Shared Issue with article?

Belzutifan Combo Improves Disease Control Vs Cabozantinib in Advanced RCC

|
By Roman Fabbricatore, Russ Conroy, Barbara Burtness
| ONCOLOGY journal Verified
Results from the phase 3 LITESPARK-011 trial (NCT04586231) showed that belzutifan (Welireg) plus lenvatinib (Lenvima) significantly improved disease control compared with cabozantinib (Cabometyx) in patients with previously treated advanced clear cell renal cell carcinoma (ccRCC), according to a news release from the Vall d'Hebron Institute of Oncology (VHIO).¹ What did the phase 3 LITESPARK-011 trial show?
Open in Who Shared Issue with article?

Evolving Treatment Strategies in Relapsed/Refractory Multiple Myeloma

|
By Barbara Burtness, Russ Conroy, Ariana Pelosci Verified
| ONCOLOGY journal Verified
During a Training Academy hosted by CancerNetwork®, a panel of experts gathered to discuss patient identification, emerging clinical data, and case-based sequencing considerations for BCMA-directed bispecific antibodies in early-relapse multiple myeloma. The panel was moderated by Binod Dhakal, MD, a professor of medicine at the Medical College of Wisconsin, and a hematologist at the Clinical Cancer Center at Froedtert Hospital in Milwaukee, Wisconsin.
Open in Who Shared Issue with article?
See all 45 licensed articles (63 Total)